Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Non-Current Assets (2021 - 2026)

Summit Therapeutics filings provide 6 years of Other Non-Current Assets readings, the most recent being $8.2 million for Q1 2026.

  • Quarterly Other Non-Current Assets rose 98.58% to $8.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Mar 2026, up 98.58% year-over-year, with the annual reading at $7.2 million for FY2025, 182.77% up from the prior year.
  • Other Non-Current Assets hit $8.2 million in Q1 2026 for Summit Therapeutics, up from $7.2 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $8.2 million in Q1 2026 and bottomed at $140000.0 in Q3 2022.
  • Average Other Non-Current Assets over 5 years is $3.0 million, with a median of $1.9 million recorded in 2024.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 2994.29% in 2023 before it tumbled 56.99% in 2024.
  • Summit Therapeutics' Other Non-Current Assets stood at $577000.0 in 2022, then surged by 649.05% to $4.3 million in 2023, then tumbled by 41.05% to $2.5 million in 2024, then surged by 182.77% to $7.2 million in 2025, then increased by 14.24% to $8.2 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Other Non-Current Assets are $8.2 million (Q1 2026), $7.2 million (Q4 2025), and $7.0 million (Q3 2025).